ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1411

The Peroxisome Proliferator Activated Receptor-gamma pioglitazone Decreases Cardiovascular Risk and Disease Activity In Patients With Rheumatoid arthritis 

Wendy Marder1, Shokoufeh Khalatbari2, James D. Myles3, Rita Hench4, Susan Lustig4, Srilakshmi Yalavarthi5, Aishwarya Parameswaran4, Robert Brook2 and Mariana J. Kaplan6, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Medicine, University of Michigan at Ann Arbor, Ann Arbor, MI, 3Michigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor, MI, 4University of Michigan, Ann Arbor, MI, 5University of Michigan Rheumatology, Ann Arbor, MI, 6Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, inflammation and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Rheumatoid arthritis (RA) is associated with heightened mortality due to atherosclerotic cardiovascular disease (CVD). Inflammatory pathways in RA negatively affect vascular physiology and promote metabolic disturbances that contribute to CVD. We hypothesized that the peroxisome proliferator activated receptor-γ (PPAR-γ) pioglitazone could promote potent vasculoprotective and anti-inflammatory effects in RA, thereby decreasing CV risk and RA disease activity. 

Methods:

143 non-diabetic adult RA patients (76.2% female, age 55.2 ± 12.1 (mean +SD) on stable RA standard of care treatment were enrolled in a randomized, double- blind placebo controlled crossover trial of 45 mg daily pioglitazone versus placebo, with a 3 month duration/arm with a 2 month-washout period. Brachial artery flow mediated dilatation (FMD), nitroglycerin mediated dilatation (NMD), pulse wave velocity of the aorta (PWV), microvascular endothelial function (reactive hyperemia index [RHI]) and circulating biomarkers of inflammation, insulin resistance and atherosclerosis risk were quantified. RA disease activity was assessed with the 28 Joint-Disease Activity Scale-C-reactive protein (DAS28-CRP) and the SF-36 quality of life questionnaire. 

Results:

When added to standard of care RA treatment, pioglitazone significantly decreased pulse wave velocity (i.e., aortic stiffness) (p=0.01), while FMD and RHI remained unchanged when compared to treatment with placebo. Further, pioglitazone significantly reduced RA disease activity (p=0.02) and CRP levels (p=0.001), while improving lipid profiles. The drug was well tolerated. 

Conclusion:

Addition of pioglitazone to RA standard of care significantly improves aortic elasticity and decreases inflammation and disease activity with minimal safety issues.  


Disclosure:

W. Marder,
None;

S. Khalatbari,
None;

J. D. Myles,
None;

R. Hench,
None;

S. Lustig,
None;

S. Yalavarthi,
None;

A. Parameswaran,
None;

R. Brook,
None;

M. J. Kaplan,

Takeda Pharmaceuticals, U.S.A., Inc.,

9.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-peroxisome-proliferator-activated-receptor-gamma-pioglitazone-decreases-cardiovascular-risk-and-disease-activity-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences